Clinical trials that rely on subjective or semi-subjective endpoints, such as clinician-reported outcomes or patient-reported symptoms, face distinct challenges when it comes to data integrity.
This PharmaTimes Magazine article, written by Janet Overvelde, Indero’s Senior Director, Project Management, highlights some lessons learned in the dermatology field, which relies heavily on subjective outcomes, and outlines strategies for improving data integrity.